IsoRay’s Cesium-131
IsoRay’s Cesium-131
IsoRay’s Cesium-131 Isotope Produces Excellent Results in Treating Metastatic Brain Cancer as Published in the Journal of Neurosurgery
100% Local (Resection Cavity) Freedom From Progression With 19.3 Month Median Follow-Up
Richland, WA (August 5, 2014) – – IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the publication of the first major peer reviewed study showing superior results using IsoRay’s Cesium-131 seeds in the treatment of metastatic brain cancer.
Powered by:ladies Shokoofe Karimpour ,Fateme Moridi ,Maryam Shokri
+ نوشته شده در ساعت 8:22  توسط جواد رمضانی |